Member Info for Saxondale

Bit of a tick up on the Nas - 4.5% up with about 200k volume - all coming in last hour or so .

Someone got a hunch that news coming next week ? or maybe just a few people deciding now is a good time to top up .

This drop has been good timing for me . Trebled my holding this morning .

Ive doubled down on GGP too . No rush the realise the profit , and likewise this is my biggest holding . Only other major one is Avacta . Luckily got in big too there after their horrendous placing . I'm hoping all 3 will do me well into my old age .

To be in a finalist group with Avacata is solid recognition . At some point with these two - some BP will step in and hoover up . Both have science days coming up , and further data to be released - all looking great . Sooner or later the shenanigans with SP will have to stop . As for GGP , its just sit and wait for the gold to start pouring .

As for news here , I expect we will get a R&D date - but we may also get some topline data to start with . I think they've done that in the past , so I expect to see some basic new trial data in September - followed by detailed plans and explanations in Oct at the R&D day . Also we have a Proactive evening in Oct (8-9th I think) .

News could come anytime ref a partner . P2 doesn't have to complete if data is so compelling . Also partner for Solid tumour Bexcombo perhaps . as that is being initiated .

Great to be included in this . I wont get too excited as I think Synairgen got nominated one year too , and we all know how that ended up . But nice recognition for us and Avacta too . Luckily , I don't think we have much worry of going down the Synairgen route anymore .

Thanks Mathiaso .

Petri Bono came over very well - straight forward and very confident . Good that we have a CMO that can do the talking stuff too , and let Juho get on with the deal making .

From the translation - nothing new regarding Partnering - he says he will leave that to the CEO , but said that with the 2 recent FDA bits of news - Faron have become even more interesting to BP .

Competition - we are first in class and market leader in our field . Nobody else is involved with Clever 1 - so we are in a class of our own - no like for like competitors .

Reason he moved to Faron - just saw the huge potential of Bex - as its first combi trial shoed such impressive response ( 79% so far ) - he saw the huge potential of Bex in other combi studies .

$25B a year market in solid tumours - and he sees Bex as being able to be part of all of that - as we are an immune enhancing drug that doesnt discriminate .

Many drugs in this field have failed due to tolerability problems - Bex has a fantastic safety and tolerability record .

Also - Matins allowed Faron to fine tune the most effective dosing levels and dosing frequency , and also define the most important biomarkers for selecting patients most likely to respond .

Why invest or stay invested - big big potential for Bex to be used in so many areas in combination .

Also - Fast track should mean very quick move to market . Expects a partner to take us there ( no way Faron will go it alone as no sales organisation ) . 2026 - although FDA involvement could be sooner .

Partnering news could come any time ( my opinion) as they would come in well before it got approval .

Next update will give us topline data - then the detailed data will come out at ASH and further expos .

R&D day in Oct giving update to pipeline plans also .

Thanks SB .

I think our Dr Bono is going to be a huge asset himself going forward .

Markku said years ago that Bexcombo was going to be the big one to watch for generating value .

I wonder who is lining up to partner that one ?

Traders , accumulators , investors , BP taking positions. All welcome . No shorters though please .

I reckon the huge volume yesterday was a bit of profit taking from certain entities , but theres no shortage of demand - The FTD was just a footnote really , good news , but not a gamechanger .

What was more interesting was the interest shown by some notable industry people , and the confidence brimming over in where this is heading .

Partner question .

Discussions are ongoing - and obviously can not be discussed in any detail - but Juho says hold and remain strong .

They are expecting to partner for P3 and not be raising any funds .

Petri Bono also now speaking -

suprise star guest !

Very enthusiastic , and also very highly regarded scientist .

FTD - eligability for acclerated approval .

H2 - what to expect next ?

R&D day coming up - with update on latest P2 in October - and expanding pipeline .

MDS recruitment - running well - expected to be completed by Q4 - current plan is next data release will be shown at ASH conference . response rates etc .

In solid tumours - progress in pipeline - Pd1 combo trial in preparation - firt trial site will be at Royal Marsden in London

Faron now has the largest trading volume on Helsinki North , and also one of the largest companies now on Helsinki North.

Aiming to complete P2 recruitment in 2024 .

They are now the Leading macrophage prorgamming agent in the industry ( if you look at the results )

Even though some of us are in good profit again - many will still have averages around this area , and many will be waiting for the rerate once a deal is done , so I can understand why they would be struggling to get people to part with any quantity at the moment without seriously raising the price .

Also the UNC Lineberger Comprehensive Cancer Center in North Carolina is now marked as 'RECRUITING' .

Joab Williamson is now the main contact . He is the Director of Clinical Operations at Faron .

So that makes 8 trial sites in total now up and running . 4 in the US and 4 in Finland .

Redeye will be coming out with a new valuation after results - also factoring in the hugely expanded and accelerated market approval opportunity .

Just realised that my last post was classic ' rampmeister ' . Can't help it lol .

M&A activity driven by clinical validation with programs at phase 2 stage (53% of deal value).

Whose hats are in the ring so far ?

Bayer ? BMS ? Novartis ?

Bidding process ?

Great find Itsall - they are all coming out from cover now .

How about this post from Jesus a month ago - and as you say ,he is the Business . Development and Licensing Director Novartis - $45 billion turnover - 8th biggest pharma co in world .

Q2 2024 Licensing vs. M&A deal landscape comparison

- Licensing activity driven by discovery / preclinical stage deals (76% of deal value). oncology remains a key priority area (47% of deal value). Small molecules remain the dominant modality (43% of deal value)

- M&A activity driven by clinical validation with programs at phase 2 stage (53% of deal value). Oncology remains a key contributor to deal value while Immunology grows (38% / 34% of deal value respectively). Protein biologics is the most common modality (54% of deal value)

Despite his zealous positivity during a low phase for Faron - I don't think we need any rampmeisters anymore . Big boys are paying attention . Facts will speak louder than any predictions now .

No P3 trial required for approval in r/r MDS - but the small P3 they will do will get them approval for front line patients too . To quote - the cornerstone treatment . Even Petri Bono was on twitter yesterday noting his excitement .

It's all finally coming together CB . The long awaited SSV is just over that next hill !

DR Bono has only been in his post for 10 days - and this drops . No wonder he took the job .

This FDA Fast Track Designation significantly strengthens bexmarilimab's position to become a new cornerstone treatment of r/r MDS and will facilitate the development of bexmarilimab for full market approval in r/r MDS. It also represents a significant additional recognition of the potential of myeloid cell reprogramming in overcoming resistance and activating immune system in the treatment of various hematological and solid tumors" says Dr. Bono, the CMO of Faron.